Literature DB >> 1989909

Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy.

J P Curtin1, W J Hoskins, S C Rubin, W B Jones, T B Hakes, M M Markman, B Reichman, L Almadrones, J L Lewis.   

Abstract

Fifty-six episodes of chemotherapy-induced neutropenia and fever occurred in forty-three patients receiving cisplatin-based combination chemotherapy for ovarian cancer. All patients were treated with broad-spectrum antibiotics including gentamicin. Twelve of fifty-six episodes were associated with positive cultures; in six patients a single organism was isolated, and the other six patients had polymicrobial infection. The mean duration of antibiotic therapy was 6.5 days. One patient died of sepsis. Fifty-five episodes had a successful outcome. There was no antibiotic-related morbidity. Based on this review we recommend broad-spectrum antibiotic therapy for chemotherapy-induced neutropenia with fever. The regimen of gentamicin plus ticarcillin and clavulanic acid (ceftazidime for penicillin-allergic patients) is effective as initial therapy. Additional agents (i.e., vancomycin) may be necessary in culture-positive patients based on sensitivity testing of bacterial isolates. Gentamicin can be safely administered to patients receiving cisplatin-based chemotherapy without compromising ability to continue cisplatin therapy in subsequent treatment cycles.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989909     DOI: 10.1016/0090-8258(91)90077-i

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  1 in total

1.  New in vitro highly cytotoxic platinum and palladium cyanoximates with minimal side effects in vivo.

Authors:  Stephanie D Dannen; Lauren Cornelison; Paul Durham; John E Morley; Kiana Shahverdi; Junwei Du; Haiying Zhou; Leland C Sudlow; Daniel Hunter; Matthew D Wood; Mikhail Y Berezin; Nikolay Gerasimchuk
Journal:  J Inorg Biochem       Date:  2020-05-06       Impact factor: 4.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.